Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Ther

Name: Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Ther
Start: 2032-12-30

December 30, 2032

Company: TuHURA Biosciences, Inc./NV (HURA)
Drug: ifx-hu2
Indication: Advanced Or Metastatic Merkel Cell Carcinoma

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Ther — HURA Phase 3 Readout | BioSniper